Greenbrook TMS (NASDAQ: GBNH) is one of 28 public companies in the “Miscellaneous health & allied services, not elsewhere classified” industry, but how does it compare to its rivals? We will compare Greenbrook TMS to similar companies based on the strength of its earnings, institutional ownership, risk, valuation, profitability, analyst recommendations and dividends.
Valuation & Earnings
This table compares Greenbrook TMS and its rivals top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Greenbrook TMS||$43.13 million||-$29.66 million||-5.30|
|Greenbrook TMS Competitors||$1.90 billion||$87.95 million||34.84|
This is a breakdown of recent ratings for Greenbrook TMS and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Greenbrook TMS Competitors||93||397||550||15||2.46|
Greenbrook TMS presently has a consensus price target of $16.13, indicating a potential upside of 31.10%. As a group, “Miscellaneous health & allied services, not elsewhere classified” companies have a potential upside of 22.40%. Given Greenbrook TMS’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Greenbrook TMS is more favorable than its rivals.
This table compares Greenbrook TMS and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Greenbrook TMS Competitors||-39.07%||-3.98%||-9.95%|
Institutional & Insider Ownership
0.8% of Greenbrook TMS shares are owned by institutional investors. Comparatively, 43.7% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are owned by institutional investors. 25.3% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
About Greenbrook TMS
Greenbrook TMS Inc., together with its subsidiaries, controls and operates a network of outpatient mental health services centers in the United States. Its centers specialize in the provision of transcranial magnetic stimulation therapy, an FDA-cleared non-invasive therapy for the treatment of depression and related psychiatric services. The company operates approximately 128 treatment centers. Greenbrook TMS Inc. was founded in 2011 and is headquartered in Toronto, Canada.
Receive News & Ratings for Greenbrook TMS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenbrook TMS and related companies with MarketBeat.com's FREE daily email newsletter.